Medicines Patent Pool/BMS Deal On Atazanavir To Benefit 110 Developing Countries, But Not China And Brazil
This article was originally published in PharmAsia News
The Medicines Patent Pool’s deal with BMS for licenses for the manufacture and supply of atazanavir for low- to middle-income countries will benefit up to a million HIV sufferers.
You may also be interested in...
FDA’s Antiviral Drugs Advisory Committee takes up the four-drug HIV-1 regimen, which includes two new agents, on May 11. The firm hopes to be able to sell the combination in part on its favorable side effects profile if the product is approved.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.